Raymond James Financial
RANI icon

Raymond James Financial’s Rani Therapeutics RANI Stock Holding History

Raymond James Financial’s Portfolio RANI Stock Details RANI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-2,954
Closed -$1.52K – 6349
2025
Q2 		$1.52K Buy
+2,954
New +$2.41K ﹤0.01% 6477

Other funds holding RANI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NFGH
Nan Fung Group Holdings Kai Tak, Hong Kong $121M AUM 56.89% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
USAA
United Services Automobile Association San Antonio, Texas $851M AUM 5.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
KPWS
Kestra Private Wealth Services Austin, Texas $9.1B AUM 32.09% 1-Year Est. Return
TPC
Takeda Pharmaceutical Company Tokyo, Japan $16.4M AUM 195.92% 1-Year Est. Return
CAMG
CWA Asset Management Group Naples, Florida $3.28B AUM 34.07% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return

Raymond James Financial's RANI Position: Q3 2025 in Review

Raymond James Financial sold out of Rani Therapeutics (RANI) in Q3 2025, closing a stake of 2,954 shares — an estimated $1.52K sold.

Raymond James Financial first reported a position in RANI in Q2 2025 and held it in 1 quarter. The position peaked at $1.52K in Q2 2025. 38 funds tracked by Wall St. Rank hold RANI as of Q3 2025.

  • Raymond James Financial reported no remaining Rani Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Raymond James Financial sold 2,954 Rani Therapeutics shares in Q3 2025, an estimated $1.52K.
  • Raymond James Financial first reported a position in Rani Therapeutics in Q2 2025 and held it in 1 quarter.
  • Raymond James Financial's Rani Therapeutics position peaked at $1.52K in Q2 2025.
  • 38 funds tracked by Wall St. Rank held Rani Therapeutics as of Q3 2025.

Based on Raymond James Financial's 13F filing for Q3 2025, filed 14 Nov 2025.